1. Home
  2. FOA vs BDTX Comparison

FOA vs BDTX Comparison

Compare FOA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finance of America Companies Inc.

FOA

Finance of America Companies Inc.

HOLD

Current Price

$19.70

Market Cap

177.1M

Sector

Finance

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.97

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOA
BDTX
Founded
2013
2014
Country
United States
United States
Employees
784
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.1M
171.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FOA
BDTX
Price
$19.70
$1.97
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$26.00
$9.67
AVG Volume (30 Days)
46.7K
2.0M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
130.71
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$0.58
N/A
Revenue Next Year
$6.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.77
$1.93
52 Week High
$29.58
$4.94

Technical Indicators

Market Signals
Indicator
FOA
BDTX
Relative Strength Index (RSI) 48.96 35.86
Support Level $19.00 N/A
Resistance Level $20.17 $2.30
Average True Range (ATR) 0.80 0.30
MACD 0.01 -0.08
Stochastic Oscillator 67.37 0.75

Price Performance

Historical Comparison
FOA
BDTX

About FOA Finance of America Companies Inc.

Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: